{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:48:29Z","timestamp":1793134109405,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.yebeh.2021.108311","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T05:51:38Z","timestamp":1631598698000},"page":"108311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Drugs for patients with epilepsy and excessive daytime sleepiness"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2416-147X","authenticated-orcid":false,"given":"Gaetano","family":"Zaccara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5683-1941","authenticated-orcid":false,"given":"Emanuele","family":"Bartolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Tramacere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.108311_b0005","article-title":"Methylphenidate for attention problems in epilepsy patients: Safety and efficacy","volume":"115","author":"Leeman-Markowski","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108311_b0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.seizure.2020.09.031","article-title":"Cognitive disorders in epilepsy II: Clinical targets, indications and selection of test instruments","volume":"83","author":"Helmstaedter","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108311_b0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11325-019-01921-4","article-title":"Excessive daytime sleepiness and fatigue in neurological disorders","volume":"24","author":"Maestri","year":"2020","journal-title":"Sleep Breath"},{"key":"10.1016\/j.yebeh.2021.108311_b0020","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00415-012-6526-2","article-title":"Should cognition be screened in new-onset epilepsies? A study in 247 untreated patients","volume":"259","author":"Witt","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2021.108311_b0025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrneurol.2011.3","article-title":"The neurobiology of cognitive disorders in temporal lobe epilepsy","volume":"7","author":"Bell","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.yebeh.2021.108311_b0030","first-page":"845","article-title":"Sleep neurobiology from a clinical perspective","volume":"34","author":"Espa\u00f1a","year":"2011","journal-title":"Sleep"},{"key":"10.1016\/j.yebeh.2021.108311_b0035","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/jnnp-2017-315732","article-title":"Functional connectivity disturbances of the ascending reticular activating system in temporal lobe epilepsy","volume":"88","author":"Englot","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2021.108311_b0040","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.12852","article-title":"Definition of excessive daytime sleepiness in the general population: Feeling sleepy relates better to sleep-related symptoms and quality of life than the Epworth Sleepiness Scale score. Results from an epidemiological study","volume":"28","author":"Thorarinsdottir","year":"2019","journal-title":"J Sleep Res"},{"key":"10.1016\/j.yebeh.2021.108311_b0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM199601113340207","article-title":"Obstructive sleep apnea","volume":"334","author":"Strollo","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2021.108311_b0050","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1056\/NEJM199304293281704","article-title":"The occurrence of sleep-disordered breathing among middle-aged adults","volume":"328","author":"Young","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2021.108311_b0055","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/sleep\/20.12.1105","article-title":"Predictors of sleepiness in epilepsy patients","volume":"20","author":"Malow","year":"1997","journal-title":"Sleep"},{"key":"10.1016\/j.yebeh.2021.108311_b0060","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.2165\/00003495-200363240-00003","article-title":"Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management","volume":"63","author":"Happe","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2021.108311_b0065","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11325-016-1391-3","article-title":"Obstructive sleep apnoea in patients with epilepsy: a meta-analysis","volume":"21","author":"Lin","year":"2017","journal-title":"Sleep Breath"},{"key":"10.1016\/j.yebeh.2021.108311_b0070","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11325-014-1076-8","article-title":"Sleep apneas and epilepsy comorbidity in childhood: a systematic review of the literature","volume":"19","author":"Gogou","year":"2015","journal-title":"Sleep Breath"},{"key":"10.1016\/j.yebeh.2021.108311_b0075","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001106.pub2","article-title":"Continuous positive airways pressure for obstructive sleep apnoea in adults","volume":"3","author":"Giles","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2021.108311_b0080","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1183\/09031936.00016808","article-title":"Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: the French multicentre study","volume":"33","author":"P\u00e9pin","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.yebeh.2021.108311_b0085","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/629469","article-title":"Excessive daytime sleepiness and epilepsy: a systematic review","author":"Giorelli","year":"2013","journal-title":"Epilepsy Res Treat"},{"key":"10.1016\/j.yebeh.2021.108311_b0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.sleep.2019.07.022","article-title":"Prevalence of attention deficit hyperactivity disorder symptoms in narcolepsy: a systematic review","volume":"65","author":"Kim","year":"2020","journal-title":"Sleep Med"},{"key":"10.1016\/j.yebeh.2021.108311_b0095","doi-asserted-by":"crossref","first-page":"293e7","DOI":"10.1016\/j.psychres.2006.02.009","article-title":"Possible confusion between primary hypersomnia and adult attention-deficit\/hyperactivity disorder","volume":"143","author":"Oosterloo","year":"2006","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.yebeh.2021.108311_b0100","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1744-9081-2-40","article-title":"Altered pattern of brain dopamine synthesis in male adolescents with attention deficit hyperactivity disorder","volume":"2","author":"Forssberg","year":"2006","journal-title":"Behav Brain Funct"},{"key":"10.1016\/j.yebeh.2021.108311_b0105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jsmc.2018.03.002","article-title":"Sleep-wake neurochemistry","volume":"13","author":"Holst","year":"2018","journal-title":"Sleep Med Clin"},{"key":"10.1016\/j.yebeh.2021.108311_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2021.101466","article-title":"Sleep quality and daytime sleepiness in epilepsy: Systematic review and meta-analysis of 25 studies including 8,196 individuals","volume":"57","author":"Bergmann","year":"2021","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.yebeh.2021.108311_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138004","article-title":"Attention deficit hyperactivity disorder symptoms, sleepiness and accidental risk in 36140 regularly registered highway drivers","volume":"10","author":"Philip","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.yebeh.2021.108311_b0120","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s11920-014-0524-2","article-title":"Wake-promoting pharmacotherapy for psychiatric disorders","volume":"16","author":"Dell'Osso","year":"2014","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.yebeh.2021.108311_b0125","doi-asserted-by":"crossref","unstructured":"Unknown. Adverse reactions to antiepileptic drugs: a follow-up study of 355 patients with chronic antiepileptic drug treatment. Collaborative Group for Epidemiology of Epilepsy. Epilepsia 1988; 29: 787-793.","DOI":"10.1111\/j.1528-1157.1988.tb04236.x"},{"key":"10.1016\/j.yebeh.2021.108311_b0130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00023210-200923020-00003","article-title":"Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors","volume":"23","author":"Mula","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2021.108311_b0135","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1212\/WNL.0000000000002545","article-title":"Brivaracetam add-on for refractory focal epilepsy: A systematic review and meta-analysis","volume":"86","author":"Lattanzi","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.108311_b0140","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","article-title":"Efficacy and safety of cannabidiol in epilepsy: A systematic review and meta-analysis","volume":"78","author":"Lattanzi","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2021.108311_b0145","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40263-020-00759-9","article-title":"Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis","volume":"34","author":"Lattanzi","year":"2020","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.yebeh.2021.108311_b0150","article-title":"Eslicarbazepine acetate add-on for drug-resistant partial epilepsy","volume":"10","author":"Chang","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.yebeh.2021.108311_b0155","article-title":"Gabapentin add-on treatment for drug-resistant focal epilepsy","volume":"10","author":"Panebianco","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2021.108311_b0160","article-title":"Lacosamide add-on therapy for partial epilepsy","volume":"6","author":"Weston","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2021.108311_b0165","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1528-1167.2012.03589.x","article-title":"The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Zaccara","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108311_b0170","doi-asserted-by":"crossref","unstructured":"Panebianco M, Bresnahan R, Ramaratnam S, Marson AG. Lamotrigine add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2020;3(3):CD001909.","DOI":"10.1002\/14651858.CD001909.pub3"},{"key":"10.1016\/j.yebeh.2021.108311_b0175","doi-asserted-by":"crossref","unstructured":"Cao Y, He X, Zhao L, He Y, Wang S, Zhang T, Jiang J. Efficacy and safety of Levetiracetam as adjunctive treatment in children with focal onset seizures: A systematic review and meta-analysis. Epilepsy Res.2019; 153 40-48.","DOI":"10.1016\/j.eplepsyres.2019.04.001"},{"key":"10.1016\/j.yebeh.2021.108311_b0180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.seizure.2015.07.004","article-title":"The adverse event profile of levetiracetam: A meta-analysis on children and adults","volume":"31","author":"Verrotti","year":"2015","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108311_b0185","article-title":"Oxcarbazepine add-on for drug-resistant focal epilepsy","volume":"3","author":"Bresnahan","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2021.108311_b0190","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/ene.12170","article-title":"The adverse event profile of perampanel: meta-analysis of randomized controlled trials","volume":"20","author":"Zaccara","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.yebeh.2021.108311_b0195","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005612.pub3","article-title":"Pregabalin add-on for drug-resistant partial epilepsy","author":"Pulman","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2021.108311_b0200","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","article-title":"The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Zaccara","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108311_b0205","article-title":"Rufinamide add-on therapy for drug-resistant epilepsy","volume":"11","author":"Panebianco","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2021.108311_b0210","doi-asserted-by":"crossref","unstructured":"Pulman J, Jette N, Dykeman J, Hemming K, Hutton JL, Marson AG. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2014;(2):CD001417.b","DOI":"10.1002\/14651858.CD001417.pub3"},{"issue":"7","key":"10.1016\/j.yebeh.2021.108311_b0215","article-title":"Zonisamide add-on therapy for focal epilepsy","volume":"7","author":"Brigo","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2021.108311_b0220","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.seizure.2013.03.016","article-title":"Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine","volume":"22","author":"Zaccara","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108311_b0225","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/jcb.25936","article-title":"Evaluate the efficacy and safety of anti-epileptic medications for partial seizures of epilepsy: A network meta-analysis","volume":"118","author":"Zhao","year":"2017","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.yebeh.2021.108311_b0230","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41598-017-02525-2","article-title":"Efficacy and tolerability of second and third generation anti-epileptic drugs in refractory epilepsy: a network meta-analysis","volume":"7","author":"Zhuo","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.yebeh.2021.108311_b0235","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hup.579","article-title":"Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects","volume":"19","author":"Leonard","year":"2004","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"10.1016\/j.yebeh.2021.108311_b0240","unstructured":"Methylphenidate. Summary of product characteristics https:\/\/www.medicines.org.uk\/emc\/product\/8726\/smpc#PHARMACOLOGICAL_PROPS. (consulted on March 2021)."},{"key":"10.1016\/j.yebeh.2021.108311_b0245","unstructured":"Modafinil. Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/4319\/smpc#gref (consulted on May 2021)."},{"key":"10.1016\/j.yebeh.2021.108311_b0250","unstructured":"Armodafinil. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021875s023lbl.pdf (consulted on April, 2021)."},{"key":"10.1016\/j.yebeh.2021.108311_b0255","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/jpet.118.248120","article-title":"Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor","volume":"366","author":"Baladi","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.yebeh.2021.108311_b0260","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2147\/DDDT.S101145","article-title":"Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy","volume":"12","author":"Romigi","year":"2018","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.yebeh.2021.108311_b0265","unstructured":"Pitolisant. Summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/7402\/smpc#gref (consulted on May, 2021)."},{"key":"10.1016\/j.yebeh.2021.108311_b0270","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.clinthera.2018.12.001","article-title":"A phase I, randomized, crossover, open-label study of the pharmacokinetics of solriamfetol (JZP-110) in healthy adult subjects with and without food","volume":"41","author":"Zomorodi","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.yebeh.2021.108311_b0275","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/NSS.S103462","article-title":"Update on the treatment of narcolepsy: clinical efficacy of pitolisant","volume":"9","author":"Calik","year":"2017","journal-title":"Nat Sci Sleep"},{"key":"10.1016\/j.yebeh.2021.108311_b0280","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.sleep.2019.09.001","article-title":"Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications","volume":"68","author":"Thorpy","year":"2020","journal-title":"Sleep Med"},{"key":"10.1016\/j.yebeh.2021.108311_b0285","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/epi.14549","article-title":"Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission","volume":"59","author":"Auvin","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108311_b0290","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","article-title":"Recently approved and upcoming treatments for narcolepsy","volume":"34","author":"Thorpy","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2021.108311_b0295","doi-asserted-by":"crossref","unstructured":"Subedi R, Singh R, Thakur RK, KCB, Jha D, Ray BK. Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials. Sleep Med. 2020; 75: 510-521.","DOI":"10.1016\/j.sleep.2020.09.019"},{"key":"10.1016\/j.yebeh.2021.108311_b0300","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.pnpbp.2007.10.016","article-title":"Placebo and modafinil effect on sleepiness in obstructive sleep apnea","volume":"32","author":"Bittencourt","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.yebeh.2021.108311_b0305","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5664\/jcsm.2912","article-title":"Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated Japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study","volume":"9","author":"Inoue","year":"2013","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.yebeh.2021.108311_b0310","article-title":"Obstructive sleep apnea patients adhering to continuous positive airway pressure: a randomized trial","author":"P\u00e9pin","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.yebeh.2021.108311_b0315","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1164\/rccm.201907-1284OC","article-title":"Pitolisant for daytime sleepiness in patients with obstructive sleep apnea who refuse continuous positive airway pressure treatment. a randomized trial","volume":"201","author":"Dauvilliers","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.yebeh.2021.108311_b0320","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.chest.2018.11.005","article-title":"Solriamfetol for the treatment of excessive sleepiness in OSA: A placebo-controlled randomized withdrawal study","volume":"155","author":"Strollo","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.yebeh.2021.108311_b0325","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1164\/rccm.201806-1100OC","article-title":"Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3). A randomized controlled trial","volume":"199","author":"Schweitzer","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.yebeh.2021.108311_b0330","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/WNF.0000000000000159","article-title":"Exploratory phase II trial to evaluate the safety and the antiepileptic effect of pitolisant (BF2.649) in refractory partial seizures, given as adjunctive treatment during 3 months","volume":"39","author":"Collart Dutilleul","year":"2016","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2021.108311_b0335","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199005020-00004","article-title":"Clinical features, pathogenesis and management of drug-induced seizures","volume":"5","author":"Zaccara","year":"1990","journal-title":"Drug Saf"},{"key":"10.1016\/j.yebeh.2021.108311_b0340","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/bs.irn.2015.02.003","article-title":"Neurologic complications of psychomotor stimulant abuse","volume":"120","author":"Sanchez-Ramos","year":"2015","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.yebeh.2021.108311_b0345","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/add.14708","article-title":"Psychostimulant use and the brain","volume":"114","author":"Lappin","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.yebeh.2021.108311_b0350","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/dev.420130103","article-title":"Paradoxical effects of d-amphetamine upon seizure susceptibility in 2 selectively bred lines of mice","volume":"13","author":"Greer","year":"1980","journal-title":"Dev Psychobiol"},{"key":"10.1016\/j.yebeh.2021.108311_b0355","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s11064-018-2623-7","article-title":"Effects of modafinil on clonic seizure threshold induced by pentylenetetrazole in mice: involvement of glutamate, nitric oxide, GABA, and serotonin pathways","volume":"43","author":"Bahramnjead","year":"2018","journal-title":"Neurochem Res"},{"key":"10.1016\/j.yebeh.2021.108311_b0360","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00787-010-0140-6","article-title":"European guidelines on managing adverse effects of medication for ADHD","volume":"20","author":"Graham","year":"2011","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.yebeh.2021.108311_b0365","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.4088\/JCP.15f10580","article-title":"A method for deciding about the possible safety of modafinil and armodafinil in patients with seizure disorder","volume":"77","author":"Andrade","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.yebeh.2021.108311_b0370","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40263-013-0084-8","article-title":"Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management","volume":"27","author":"Spiller","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2021.108311_b0375","unstructured":"Solriamfetol. Summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/11016\/smpc#gref (Consulted on March, 2021)"},{"key":"10.1016\/j.yebeh.2021.108311_b0380","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.yebeh.2013.03.018","article-title":"Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: dose-dependent effects in the human photosensitivity model","volume":"28","author":"Kasteleijn-Nolst Trenit\u00e9","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108311_b0385","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.yebeh.2018.07.023","article-title":"Common psychiatric comorbidities in epilepsy: How big of a problem is it?","volume":"98","author":"Salpekar","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108311_b0390","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1017\/S1092852916000250","article-title":"Psychosis of epilepsy: a multifaceted neuropsychiatric disorder","volume":"21","author":"Kanner","year":"2016","journal-title":"CNS Spectr"},{"key":"10.1016\/j.yebeh.2021.108311_b0395","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40264-013-0025-y","article-title":"Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study","volume":"36","author":"Davies","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.yebeh.2021.108311_b0400","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1474-4422(15)00225-2","article-title":"Comorbidities of epilepsy: current concepts and future perspectives","volume":"15","author":"Keezer","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.108311_b0405","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.seizure.2016.10.001","article-title":"The heart of epilepsy: Current views and future concepts","volume":"44","author":"Shmuely","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108311_b0410","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1212\/WNL.0000000000003685","article-title":"Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society","volume":"88","author":"Harden","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.108311_b0415","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.yebeh.2019.05.038","article-title":"Comorbidity between epilepsy and cardiac arrhythmias: Implication for treatment","volume":"97","author":"Zaccara","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108311_b0420","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.seizure.2014.05.011","article-title":"The effects of antiepileptic drugs on vascular risk factors: a narrative review","volume":"23","author":"Katsiki","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108311_b0425","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/pds.4642","article-title":"Modafinil and the risk of cardiovascular events: Findings from three US claims databases","volume":"27","author":"Kaplan","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.yebeh.2021.108311_b0430","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","article-title":"Idiosyncratic adverse reactions to antiepileptic drugs","volume":"48","author":"Zaccara","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108311_b0435","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-3476(97)70308-1","article-title":"Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective?","volume":"130","author":"Gross-Tsur","year":"1997","journal-title":"J Pediatr"},{"key":"10.1016\/j.yebeh.2021.108311_b0440","first-page":"1081","article-title":"Methylphenidate in children with seizures and attention-deficit disorder","volume":"143","author":"Feldman","year":"1989","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.yebeh.2021.108311_b0445","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1469-8749.1988.tb04763.x","article-title":"Possible phenytoin-methylphenidate interaction","volume":"30","author":"Ghofrani","year":"1988","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2021.108311_b0450","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00004583-199902000-00006","article-title":"Carbamazepine and methylphenidate in ADHD","volume":"38","author":"Schaller","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.yebeh.2021.108311_b0455","unstructured":"Sodium oxybate. Summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/medicine\/17364\/SPC\/Xyrem+500+mg+ml+oral+solution#gref (Consulted on August, 2021)"},{"key":"10.1016\/j.yebeh.2021.108311_b0460","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.sleep.2019.06.017","article-title":"Gamma-hydroxybutyrate (GHB) for narcolepsy in adults: an updated systematic review and meta-analysis","volume":"64","author":"Xu","year":"2019","journal-title":"Sleep Med"},{"key":"10.1016\/j.yebeh.2021.108311_b0465","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.5664\/jcsm.5180","article-title":"Narcolepsy type 1 and idiopathic generalized epilepsy: diagnostic and therapeutic challenges in dual cases","volume":"11","author":"Baiardi","year":"2015","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.yebeh.2021.108311_b0470","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1007\/s00415-015-8018-7","article-title":"Analysis of nocebo effects of antiepileptic drugs across different conditions","volume":"263","author":"Zaccara","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2021.108311_b0475","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.yebeh.2006.08.010","article-title":"Subjective somnolence relates mainly to depression among patients in a tertiary care epilepsy center","volume":"9","author":"Jenssen","year":"2006","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108311_b0480","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.sleep.2020.06.033","article-title":"Effects of eslicarbazepine as add-on therapy on sleep architecture in temporal lobe epilepsy: results from \u201cEsleep\u201d study","volume":"75","author":"Romigi","year":"2020","journal-title":"Sleep Med"},{"key":"10.1016\/j.yebeh.2021.108311_b0485","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.yebeh.2013.01.008","article-title":"Insomnia symptoms in South Florida military veterans with epilepsy","volume":"27","author":"Lopez","year":"2013","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021005722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021005722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:44:27Z","timestamp":1761504267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021005722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":97,"alternative-id":["S1525505021005722"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108311","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs for patients with epilepsy and excessive daytime sleepiness","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108311"}}